| 000 | 01524 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250516094007.0 | ||
| 264 | 0 | _c20130205 | |
| 008 | 201302s 0 0 eng d | ||
| 022 | _a1097-0142 | ||
| 024 | 7 |
_a10.1002/cncr.27638 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGriffiths, Robert I | |
| 245 | 0 | 0 |
_aComparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma. _h[electronic resource] |
| 260 |
_bCancer _cDec 2012 |
||
| 300 |
_a6079-88 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Murine-Derived _xtherapeutic use |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLymphoma, Large B-Cell, Diffuse _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aQuality-Adjusted Life Years |
| 650 | 0 | 4 | _aRituximab |
| 650 | 0 | 4 | _aSEER Program |
| 650 | 0 | 4 | _aSurvival Rate |
| 700 | 1 | _aGleeson, Michelle L | |
| 700 | 1 | _aMikhael, Joseph | |
| 700 | 1 | _aDreyling, Martin H | |
| 700 | 1 | _aDanese, Mark D | |
| 773 | 0 |
_tCancer _gvol. 118 _gno. 24 _gp. 6079-88 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/cncr.27638 _zAvailable from publisher's website |
| 999 |
_c21823569 _d21823569 |
||